Shopping Cart 0
Cart Subtotal
AED 0

Genomic Health Inc (GHDX) - Product Pipeline Analysis, 2019 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 2753

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 8258

Details

Summary

Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company's commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Genomic Health Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Genomic Health Inc Company Overview

Genomic Health Inc Company Snapshot

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview

Genomic Health Inc-Pipeline Analysis Overview

Business Description

Genomic Health Inc-Key Facts

Genomic Health Inc-Major Products and Services

Genomic Health Inc Pipeline Products by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc Pipeline Products Overview

Diagnostic Test-Non Small Cell Lung Cancer

Diagnostic Test-Non Small Cell Lung Cancer Product Overview

Liquid Biopsy-Based Bladder Cancer Test

Liquid Biopsy-Based Bladder Cancer Test Product Overview

Negative Biopsy Test-Prostate Cancer

Negative Biopsy Test-Prostate Cancer Product Overview

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay Product Overview

Oncotype Dx-Kidney Cancer

Oncotype Dx-Kidney Cancer Product Overview

Oncotype Dx Colon Cancer Assay-Oxaliplatin

Oncotype Dx Colon Cancer Assay-Oxaliplatin Product Overview

Oncotype DX IVD Test

Oncotype DX IVD Test Product Overview

Oncotype DX IVD Test Clinical Trial

Oncotype SEQ-Tissue Mutation Panel

Oncotype SEQ-Tissue Mutation Panel Product Overview

Oncotype TRACK

Oncotype TRACK Product Overview

Prognostic Test-Melanoma

Prognostic Test-Melanoma Product Overview

Prognostic Test-Non-Metastatic Renal Cell Carcinoma

Prognostic Test-Non-Metastatic Renal Cell Carcinoma Product Overview

Genomic Health Inc-Key Competitors

Genomic Health Inc-Key Employees

Genomic Health Inc-Key Employee Biographies

Genomic Health Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Genomic Health Inc, Recent Developments

Jun 04, 2019: Secondary analysis of landmark TAILORx results, published in The New England Journal of Medicine, affirms unique ability of Oncotype DX Breast Recurrence Score Test to predict chemotherapy benefit, guiding adjuvant therapy with even greater precision

Jun 03, 2019: Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score Test in node-negative Breast Cancer

May 07, 2019: Genomic Health announces first quarter 2019 financial results

Mar 25, 2019: New long-term outcomes data presented at St. Gallen International Breast Cancer Conference reinforce TAILORx treatment paradigm and standard of care use for Oncotype DX Breast Recurrence Score test

Feb 20, 2019: Genomic Health reports record 2018 fourth quarter and year-end financial results and provides 2019 financial guidance

Feb 05, 2019: Oncotype DX Genomic Prostate Score established as first genomic test with prospective validation for predicting adverse pathology in newly diagnosed patients

Jan 23, 2019: Gene-expression profiling raises costs for cancer care without improving outcomes for low-risk breast cancer patients, according to researchers

Jan 14, 2019: NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer

Jan 07, 2019: Genomic Health marks more than 1 million patients worldwide who have benefited from Oncotype DX testing in personalizing cancer treatment decisions to improve outcomes

Dec 19, 2018: NICE Expands recommendation for the Oncotype DX Breast Recurrence Score Test to more patients with early-stage breast cancer within the United Kingdom

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Genomic Health Inc Pipeline Products by Equipment Type

Genomic Health Inc Pipeline Products by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview

Genomic Health Inc Pipeline Products by Equipment Type

Genomic Health Inc Pipeline Products by Indication

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc, Key Facts

Genomic Health Inc, Major Products and Services

Genomic Health Inc Number of Pipeline Products by Development Stage

Genomic Health Inc Pipeline Products Summary by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc Ongoing Clinical Trials Summary

Diagnostic Test-Non Small Cell Lung Cancer-Product Status

Diagnostic Test-Non Small Cell Lung Cancer-Product Description

Liquid Biopsy-Based Bladder Cancer Test-Product Status

Liquid Biopsy-Based Bladder Cancer Test-Product Description

Negative Biopsy Test-Prostate Cancer-Product Status

Negative Biopsy Test-Prostate Cancer-Product Description

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Status

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Description

Oncotype Dx-Kidney Cancer-Product Status

Oncotype Dx-Kidney Cancer-Product Description

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Status

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Description

Oncotype DX IVD Test-Product Status

Oncotype DX IVD Test-Product Description

Oncotype DX IVD Test-An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-receptor Positive/HER2-Negative Primary Breast Cancer

Oncotype SEQ-Tissue Mutation Panel-Product Status

Oncotype SEQ-Tissue Mutation Panel-Product Description

Oncotype TRACK-Product Status

Oncotype TRACK-Product Description

Prognostic Test-Melanoma-Product Status

Prognostic Test-Melanoma-Product Description

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Status

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Description

Genomic Health Inc, Key Employees

Genomic Health Inc, Key Employee Biographies

Genomic Health Inc, Other Locations

Genomic Health Inc, Subsidiaries

Glossary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Genomic Health Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Siemens AG

NeoGenomics Inc

Natera Inc

Roche Diagnostics International Ltd

Qiagen NV

Exact Sciences Corp

Personal Genome Diagnostics Inc

NanoString Technologies Inc

GenomeDx Biosciences Inc

Hologic Inc

MDxHealth SA

Agendia Inc

OPKO Health Inc

Myriad Genetics Inc

Grail Inc

Metamark Genetics Inc

bioTheranostics Inc

Guardant Health Inc

Danaher Corp

Bio Techne Corp

Company Profile

Company Profile Title

Summary

Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company's commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Genomic Health Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Genomic Health Inc Company Overview

Genomic Health Inc Company Snapshot

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview

Genomic Health Inc-Pipeline Analysis Overview

Business Description

Genomic Health Inc-Key Facts

Genomic Health Inc-Major Products and Services

Genomic Health Inc Pipeline Products by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc Pipeline Products Overview

Diagnostic Test-Non Small Cell Lung Cancer

Diagnostic Test-Non Small Cell Lung Cancer Product Overview

Liquid Biopsy-Based Bladder Cancer Test

Liquid Biopsy-Based Bladder Cancer Test Product Overview

Negative Biopsy Test-Prostate Cancer

Negative Biopsy Test-Prostate Cancer Product Overview

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay Product Overview

Oncotype Dx-Kidney Cancer

Oncotype Dx-Kidney Cancer Product Overview

Oncotype Dx Colon Cancer Assay-Oxaliplatin

Oncotype Dx Colon Cancer Assay-Oxaliplatin Product Overview

Oncotype DX IVD Test

Oncotype DX IVD Test Product Overview

Oncotype DX IVD Test Clinical Trial

Oncotype SEQ-Tissue Mutation Panel

Oncotype SEQ-Tissue Mutation Panel Product Overview

Oncotype TRACK

Oncotype TRACK Product Overview

Prognostic Test-Melanoma

Prognostic Test-Melanoma Product Overview

Prognostic Test-Non-Metastatic Renal Cell Carcinoma

Prognostic Test-Non-Metastatic Renal Cell Carcinoma Product Overview

Genomic Health Inc-Key Competitors

Genomic Health Inc-Key Employees

Genomic Health Inc-Key Employee Biographies

Genomic Health Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Genomic Health Inc, Recent Developments

Jun 04, 2019: Secondary analysis of landmark TAILORx results, published in The New England Journal of Medicine, affirms unique ability of Oncotype DX Breast Recurrence Score Test to predict chemotherapy benefit, guiding adjuvant therapy with even greater precision

Jun 03, 2019: Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score Test in node-negative Breast Cancer

May 07, 2019: Genomic Health announces first quarter 2019 financial results

Mar 25, 2019: New long-term outcomes data presented at St. Gallen International Breast Cancer Conference reinforce TAILORx treatment paradigm and standard of care use for Oncotype DX Breast Recurrence Score test

Feb 20, 2019: Genomic Health reports record 2018 fourth quarter and year-end financial results and provides 2019 financial guidance

Feb 05, 2019: Oncotype DX Genomic Prostate Score established as first genomic test with prospective validation for predicting adverse pathology in newly diagnosed patients

Jan 23, 2019: Gene-expression profiling raises costs for cancer care without improving outcomes for low-risk breast cancer patients, according to researchers

Jan 14, 2019: NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer

Jan 07, 2019: Genomic Health marks more than 1 million patients worldwide who have benefited from Oncotype DX testing in personalizing cancer treatment decisions to improve outcomes

Dec 19, 2018: NICE Expands recommendation for the Oncotype DX Breast Recurrence Score Test to more patients with early-stage breast cancer within the United Kingdom

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Genomic Health Inc Pipeline Products by Equipment Type

Genomic Health Inc Pipeline Products by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview

Genomic Health Inc Pipeline Products by Equipment Type

Genomic Health Inc Pipeline Products by Indication

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc, Key Facts

Genomic Health Inc, Major Products and Services

Genomic Health Inc Number of Pipeline Products by Development Stage

Genomic Health Inc Pipeline Products Summary by Development Stage

Genomic Health Inc Ongoing Clinical Trials by Trial Status

Genomic Health Inc Ongoing Clinical Trials Summary

Diagnostic Test-Non Small Cell Lung Cancer-Product Status

Diagnostic Test-Non Small Cell Lung Cancer-Product Description

Liquid Biopsy-Based Bladder Cancer Test-Product Status

Liquid Biopsy-Based Bladder Cancer Test-Product Description

Negative Biopsy Test-Prostate Cancer-Product Status

Negative Biopsy Test-Prostate Cancer-Product Description

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Status

Next Generation Sequencing Oncotype DX-Prostate Cancer Assay-Product Description

Oncotype Dx-Kidney Cancer-Product Status

Oncotype Dx-Kidney Cancer-Product Description

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Status

Oncotype Dx Colon Cancer Assay-Oxaliplatin-Product Description

Oncotype DX IVD Test-Product Status

Oncotype DX IVD Test-Product Description

Oncotype DX IVD Test-An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-receptor Positive/HER2-Negative Primary Breast Cancer

Oncotype SEQ-Tissue Mutation Panel-Product Status

Oncotype SEQ-Tissue Mutation Panel-Product Description

Oncotype TRACK-Product Status

Oncotype TRACK-Product Description

Prognostic Test-Melanoma-Product Status

Prognostic Test-Melanoma-Product Description

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Status

Prognostic Test-Non-Metastatic Renal Cell Carcinoma-Product Description

Genomic Health Inc, Key Employees

Genomic Health Inc, Key Employee Biographies

Genomic Health Inc, Other Locations

Genomic Health Inc, Subsidiaries

Glossary

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Genomic Health Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Siemens AG

NeoGenomics Inc

Natera Inc

Roche Diagnostics International Ltd

Qiagen NV

Exact Sciences Corp

Personal Genome Diagnostics Inc

NanoString Technologies Inc

GenomeDx Biosciences Inc

Hologic Inc

MDxHealth SA

Agendia Inc

OPKO Health Inc

Myriad Genetics Inc

Grail Inc

Metamark Genetics Inc

bioTheranostics Inc

Guardant Health Inc

Danaher Corp

Bio Techne Corp